The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale
- 23 June 2005
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 149 (6), 994-1002
- https://doi.org/10.1016/j.ahj.2005.03.029
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Efficacy and Bleeding Complications Among Patients Randomized to Enoxaparin or Unfractionated Heparin for Antithrombin Therapy in Non–ST-Segment Elevation Acute Coronary SyndromesJAMA, 2004
- 1077-71 The association between care and outcomes in patients with acute coronary syndrome: National results from CRUSADEJournal of the American College of Cardiology, 2004
- Early use of glycoprotein IIb/IIIa inhibitors in non–ST-elevation acute myocardial infarctionJournal of the American College of Cardiology, 2003
- Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventionsJournal of the American College of Cardiology, 2003
- Management of acute coronary syndromes in patients presenting without persistent ST-segment elevationEuropean Heart Journal, 2002
- Management of acute coronary syndromes. Variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE)European Heart Journal, 2002
- A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS)European Heart Journal, 2002
- Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trialsThe Lancet, 2002
- Antiplatelet therapyAmerican Journal Of Medicine, 1996
- Hemorrhagic Events during Therapy with Recombinant Tissue-Type Plasminogen Activator, Heparin, and Aspirin for Acute Myocardial InfarctionAnnals of Internal Medicine, 1991